You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameThioridazine
Accession NumberDB00679  (APRD00596)
TypeSmall Molecule
GroupsApproved
Description

A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p618)

Structure
Thumb
Synonyms
10-[2-(1-Methyl-2-piperidyl)ethyl]-2-methylsulfanyl-phenothiazine
2-Methylmercapto-10-(2-(N-methyl-2-piperidyl)ethyl)phenothiazine
3-Methylmercapto-N-(2'-(N-methyl-2-piperidyl)ethyl)phenothiazine
Mallorol
Malloryl
Meleril
Mellaril
Mellaril-S
Mellerets
Mellerette
Melleril
Orsanil
Sonapax
Thioridazin
Thioridazinum
Tioridazina
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Mellarilsuspension10 mgoralNovartis Pharmaceuticals Canada Inc1964-12-312001-07-30Canada
Mellarilliquid30 mgoralNovartis Pharmaceuticals Canada Inc1997-08-152001-07-30Canada
Mellaril Tab 100mgtablet100 mgoralSandoz Canada Inc1959-12-311996-09-05Canada
Mellaril Tab 10mgtablet10 mgoralSandoz Canada Inc1959-12-311997-08-12Canada
Mellaril Tab 200mgtablet200 mgoralSandoz Canada Inc1959-12-311996-09-05Canada
Mellaril Tab 25mgtablet25 mgoralSandoz Canada Inc1959-12-311996-09-05Canada
Mellaril Tab 50mgtablet50 mgoralSandoz Canada Inc1959-12-311996-09-23Canada
Novo-ridazine (thioridazine Oral Suspension) - 2 mg/mlsuspension2 mgoralNovopharm Limited1996-09-182005-08-10Canada
Novo-ridazine 100mgtablet100 mgoralNovopharm Limited1972-12-312005-08-10Canada
Novo-ridazine 10mgtablet10 mgoralNovopharm Limited1972-12-312005-08-10Canada
Novo-ridazine 25mgtablet25 mgoralNovopharm Limited1972-12-312005-08-10Canada
Novo-ridazine 50mgtablet50 mgoralNovopharm Limited1972-12-312005-08-10Canada
Novo-ridazine Tab 200mgtablet200 mgoralNovopharm Limited1973-12-312005-08-10Canada
PMS Thioridazine Tab 50mgtablet50 mgoralPharmascience Inc1984-12-312004-05-24Canada
PMS-thioridazine 100mg/tab USPtablet100 mgoralPharmascience Inc1984-12-312004-05-24Canada
PMS-thioridazine 10mg/tab USPtablet10 mgoralPharmascience Inc1984-12-312004-05-24Canada
PMS-thioridazine Solution 30mg/mlsolution30 mgoralPharmascience Inc1988-12-312004-05-24Canada
PMS-thioridazine Solution 5mg/mlsolution5 mgoralPharmascience Inc1988-12-311996-09-09Canada
PMS-thioridazine Tab 25mgtablet25 mgoralPharmascience Inc1984-12-312004-05-24Canada
Thioridazine Oral Sus 2mg/mlsuspension2 mgoralSands Pharm1972-12-311996-09-10Canada
Thioridazine Tab 10mgtablet10 mgoralDuchesnay Inc1978-12-312003-07-18Canada
Thioridazine Tab 25mgtablet25 mgoralDuchesnay Inc1978-12-312003-07-18Canada
Thioridazine Tab 50mgtablet50 mgoralDuchesnay Inc1978-12-312003-07-18Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Thioridazine Hydrochloridetablet, film coated100 mg/1oralMutual Pharmaceutical1988-10-07Not applicableUs
Thioridazine Hydrochloridetablet, film coated10 mg/1oralMylan Pharmaceuticals Inc.1983-03-15Not applicableUs
Thioridazine Hydrochloridetablet, film coated10 mg/1oralMylan Institutional Inc.1998-04-29Not applicableUs
Thioridazine Hydrochloridetablet, film coated50 mg/1oralMutual Pharmaceutical1988-10-07Not applicableUs
Thioridazine Hydrochloridetablet50 mg/1oralREMEDYREPACK INC.2011-04-04Not applicableUs
Thioridazine Hydrochloridetablet, film coated25 mg/1oralMutual Pharmaceutical1988-10-07Not applicableUs
Thioridazine Hydrochloridetablet25 mg/1oralREMEDYREPACK INC.2011-04-04Not applicableUs
Thioridazine Hydrochloridetablet, film coated10 mg/1oralMutual Pharmaceutical1988-10-07Not applicableUs
Thioridazine Hydrochloridetablet, film coated100 mg/1oralMylan Pharmaceuticals Inc.1983-11-18Not applicableUs
Thioridazine Hydrochloridetablet, film coated100 mg/1oralMylan Institutional Inc.1998-06-22Not applicableUs
Thioridazine Hydrochloridetablet, film coated50 mg/1oralMylan Pharmaceuticals Inc.1983-03-15Not applicableUs
Thioridazine Hydrochloridetablet, film coated50 mg/1oralMylan Institutional Inc.1998-05-06Not applicableUs
Thioridazine Hydrochloridetablet, film coated25 mg/1oralMylan Pharmaceuticals Inc.1983-03-15Not applicableUs
Thioridazine Hydrochloridetablet, film coated25 mg/1oralMylan Institutional Inc.1995-06-12Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AldazineNot Available
MallorolNot Available
MelerilNot Available
MelleretteNot Available
MellerettenNot Available
MellerilNot Available
NovoridazineNot Available
RidazinNot Available
RidazineNot Available
SonapaxNot Available
ThiorilNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Thioridazine Hydrochloride
130-61-0
Thumb
  • InChI Key: NZFNXWQNBYZDAQ-UHFFFAOYNA-N
  • Monoisotopic Mass: 406.130417961
  • Average Mass: 407.035
DBSALT000503
Categories
UNIIN3D6TG58NI
CAS number50-52-2
WeightAverage: 370.575
Monoisotopic: 370.153740222
Chemical FormulaC21H26N2S2
InChI KeyInChIKey=KLBQZWRITKRQQV-UHFFFAOYSA-N
InChI
InChI=1S/C21H26N2S2/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)25-21-11-10-17(24-2)15-19(21)23/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3
IUPAC Name
10-[2-(1-methylpiperidin-2-yl)ethyl]-2-(methylsulfanyl)-10H-phenothiazine
SMILES
CSC1=CC2=C(SC3=CC=CC=C3N2CCC2CCCCN2C)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzothiazines
Sub ClassPhenothiazines
Direct ParentPhenothiazines
Alternative Parents
Substituents
  • Phenothiazine
  • Alkyldiarylamine
  • Diarylthioether
  • Alkylarylthioether
  • Benzenoid
  • Piperidine
  • Para-thiazine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Sulfenyl compound
  • Thioether
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organonitrogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of schizophrenia and generalized anxiety disorder.
PharmacodynamicsThioridazine is a trifluoro-methyl phenothiazine derivative intended for the management of schizophrenia and other psychotic disorders. Thioridazine has not been shown effective in the management of behaviorial complications in patients with mental retardation.
Mechanism of actionThioridazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; blocks alpha-adrenergic effect, depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis.
Related Articles
Absorption60%
Volume of distributionNot Available
Protein binding95%
Metabolism

Hepatic

Route of eliminationNot Available
Half life21-25 hours
ClearanceNot Available
ToxicityLD50=956-1034 mg/kg (Orally in rats); Agitation, blurred vision, coma, confusion, constipation, difficulty breathing, dilated or constricted pupils, diminished flow of urine, dry mouth, dry skin, excessively high or low body temperature, extremely low blood pressure, fluid in the lungs, heart abnormalities, inability to urinate, intestinal blockage, nasal congestion, restlessness, sedation, seizures, shock
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9068
Blood Brain Barrier+0.9901
Caco-2 permeable+0.7912
P-glycoprotein substrateSubstrate0.7863
P-glycoprotein inhibitor IInhibitor0.8564
P-glycoprotein inhibitor IIInhibitor0.9115
Renal organic cation transporterInhibitor0.7943
CYP450 2C9 substrateNon-substrate0.7981
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateNon-substrate0.5068
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorNon-inhibitor0.908
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.7697
CYP450 3A4 inhibitorNon-inhibitor0.8308
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5826
Ames testNon AMES toxic0.8703
CarcinogenicityNon-carcinogens0.9528
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.5395 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.906
hERG inhibition (predictor II)Inhibitor0.8384
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Novartis pharmaceuticals corp
  • Actavis mid atlantic llc
  • Alpharma us pharmaceuticals division
  • Hi tech pharmacal co inc
  • Pharmaceutical assoc inc div beach products
  • Sandoz inc
  • Teva pharmaceuticals usa
  • Wockhardt eu operations (swiss) ag
  • Roxane laboratories inc
  • Ivax pharmaceuticals inc
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Par pharmaceutical inc
  • Superpharm corp
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • West ward pharmaceutical corp
Packagers
Dosage forms
FormRouteStrength
Liquidoral30 mg
Suspensionoral10 mg
Tabletoral100 mg
Tabletoral10 mg
Tabletoral25 mg
Tabletoral50 mg
Tabletoral200 mg
Solutionoral30 mg
Solutionoral5 mg
Tabletoral25 mg/1
Tabletoral50 mg/1
Tablet, film coatedoral10 mg/1
Tablet, film coatedoral100 mg/1
Tablet, film coatedoral25 mg/1
Tablet, film coatedoral50 mg/1
Suspensionoral2 mg
Prices
Unit descriptionCostUnit
Thioridazine hcl powder11.16USD g
Thioridazine HCl 200 mg tablet1.14USD tablet
Thioridazine HCl 150 mg tablet1.01USD tablet
Thioridazine HCl 100 mg tablet0.69USD tablet
Thioridazine 100 mg tablet0.67USD tablet
Thioridazine HCl 50 mg tablet0.61USD tablet
Thioridazine 50 mg tablet0.58USD tablet
Thioridazine HCl 25 mg tablet0.49USD tablet
Thioridazine 25 mg tablet0.47USD tablet
Thioridazine HCl 15 mg tablet0.45USD tablet
Thioridazine HCl 10 mg tablet0.35USD tablet
Thioridazine 10 mg tablet0.33USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point73 °CPhysProp
boiling point230 °C at 2.00E-02 mm HgPhysProp
water solubility0.0336 mg/LNot Available
logP5.90HANSCH,C ET AL. (1995)
pKa9.5EL TAYAR,N ET AL. (1985)
Predicted Properties
PropertyValueSource
Water Solubility0.000855 mg/mLALOGPS
logP5.93ALOGPS
logP5.47ChemAxon
logS-5.6ALOGPS
pKa (Strongest Basic)8.93ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area6.48 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity113.52 m3·mol-1ChemAxon
Polarizability43.26 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (8.15 KB)
Spectra
Spectrum TypeDescriptionSplash Key
MSMass Spectrum (Electron Ionization)splash10-006t-9552000000-ea4c5c56ee4333d0815aView in MoNA
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesN05AC02
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (44.7 KB)
Interactions
Drug Interactions
Drug
AbirateroneThe serum concentration of Thioridazine can be increased when it is combined with Abiraterone.
AclidiniumAclidinium may increase the anticholinergic activities of Thioridazine.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Thioridazine.
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
AmiodaroneThe serum concentration of Thioridazine can be increased when it is combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Thioridazine is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Thioridazine.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Thioridazine.
AmphetamineThioridazine may decrease the stimulatory activities of Amphetamine.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Thioridazine.
AtomoxetineThe serum concentration of Atomoxetine can be increased when it is combined with Thioridazine.
AzelastineThioridazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Thioridazine.
BenzphetamineThioridazine may decrease the stimulatory activities of Benzphetamine.
Botulinum Toxin Type AThioridazine may increase the anticholinergic activities of Botulinum Toxin Type A.
Botulinum Toxin Type BThioridazine may increase the anticholinergic activities of Botulinum Toxin Type B.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Thioridazine.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Thioridazine.
BromocriptineThe therapeutic efficacy of Thioridazine can be decreased when used in combination with Bromocriptine.
BuprenorphineThioridazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
BupropionThe serum concentration of Thioridazine can be increased when it is combined with Bupropion.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Thioridazine.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Thioridazine.
Calcium carbonateCalcium carbonate can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
CathinoneThioridazine may decrease the stimulatory activities of Cathinone.
CelecoxibThe serum concentration of Thioridazine can be increased when it is combined with Celecoxib.
ChloroquineThe serum concentration of Thioridazine can be increased when it is combined with Chloroquine.
ChlorphenamineChlorphenamine may increase the arrhythmogenic activities of Thioridazine.
ChlorpromazineThe serum concentration of Thioridazine can be increased when it is combined with Chlorpromazine.
CimetidineThe serum concentration of Thioridazine can be increased when it is combined with Cimetidine.
Cimetropium BromideThioridazine may increase the anticholinergic activities of Cimetropium Bromide.
CinacalcetThe serum concentration of Thioridazine can be increased when it is combined with Cinacalcet.
CitalopramCitalopram may increase the QTc-prolonging activities of Thioridazine.
ClobazamThe serum concentration of Thioridazine can be increased when it is combined with Clobazam.
ClomipramineThe serum concentration of Thioridazine can be increased when it is combined with Clomipramine.
ClozapineThe serum concentration of Thioridazine can be increased when it is combined with Clozapine.
CobicistatThe serum concentration of Thioridazine can be increased when it is combined with Cobicistat.
CocaineThe serum concentration of Thioridazine can be increased when it is combined with Cocaine.
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Thioridazine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Thioridazine.
DapoxetineDapoxetine may increase the arrhythmogenic activities of Thioridazine.
DarifenacinThe serum concentration of Thioridazine can be increased when it is combined with Darifenacin.
DarunavirThe serum concentration of Thioridazine can be increased when it is combined with Darunavir.
DelavirdineThe serum concentration of Thioridazine can be increased when it is combined with Delavirdine.
DesipramineThe serum concentration of Thioridazine can be increased when it is combined with Desipramine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Thioridazine.
DextroamphetamineThioridazine may decrease the stimulatory activities of Dextroamphetamine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Thioridazine.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Thioridazine.
DiphenhydramineThe serum concentration of Thioridazine can be increased when it is combined with Diphenhydramine.
DofetilideDofetilide may increase the QTc-prolonging activities of Thioridazine.
DonepezilDonepezil may increase the central neurotoxic activities of Thioridazine.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Thioridazine.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Thioridazine.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Thioridazine.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Thioridazine.
DronedaroneThe serum concentration of Thioridazine can be increased when it is combined with Dronedarone.
DuloxetineThe serum concentration of Thioridazine can be increased when it is combined with Duloxetine.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Thioridazine.
EliglustatThe serum concentration of Thioridazine can be increased when it is combined with Eliglustat.
EluxadolineThioridazine may increase the activities of Eluxadoline.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Thioridazine.
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Thioridazine.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Thioridazine.
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Thioridazine.
EthanolThioridazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Thioridazine.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Thioridazine.
FluoxetineFluoxetine may increase the QTc-prolonging activities of Thioridazine.
FluvoxamineThe serum concentration of Thioridazine can be increased when it is combined with Fluvoxamine.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Thioridazine.
GalantamineGalantamine may increase the central neurotoxic activities of Thioridazine.
Glucagon recombinantThe risk or severity of adverse effects can be increased when Thioridazine is combined with Glucagon recombinant.
GoserelinGoserelin may increase the QTc-prolonging activities of Thioridazine.
HaloperidolThe serum concentration of Thioridazine can be increased when it is combined with Haloperidol.
HydrocodoneThioridazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
ImipramineThe serum concentration of Thioridazine can be increased when it is combined with Imipramine.
Ipratropium bromideIpratropium bromide may increase the anticholinergic activities of Thioridazine.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Thioridazine.
IsoniazidThe serum concentration of Thioridazine can be increased when it is combined with Isoniazid.
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Thioridazine.
IvabradineIvabradine may increase the QTc-prolonging activities of Thioridazine.
KetoconazoleThe serum concentration of Thioridazine can be increased when it is combined with Ketoconazole.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Thioridazine.
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Thioridazine.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Thioridazine.
LisdexamfetamineThioridazine may decrease the stimulatory activities of Lisdexamfetamine.
LithiumLithium may increase the neurotoxic activities of Thioridazine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Thioridazine.
LorcaserinThe serum concentration of Thioridazine can be increased when it is combined with Lorcaserin.
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Thioridazine.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Thioridazine.
MequitazineThe serum concentration of Mequitazine can be increased when it is combined with Thioridazine.
MethadoneThe serum concentration of Thioridazine can be increased when it is combined with Methadone.
MethamphetamineThioridazine may decrease the stimulatory activities of Methamphetamine.
MethotrimeprazineThe serum concentration of Thioridazine can be increased when it is combined with Methotrimeprazine.
MethylphenidateThe risk or severity of adverse effects can be increased when Thioridazine is combined with Methylphenidate.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Thioridazine.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Thioridazine.
MetyrosineThioridazine may increase the sedative activities of Metyrosine.
MifepristoneMifepristone may increase the QTc-prolonging activities of Thioridazine.
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Thioridazine.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Thioridazine.
MirabegronThe serum concentration of Thioridazine can be increased when it is combined with Mirabegron.
MoclobemideThe serum concentration of Thioridazine can be increased when it is combined with Moclobemide.
MorphineThioridazine may increase the hypotensive activities of Morphine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Thioridazine.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Thioridazine.
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Thioridazine.
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Thioridazine.
NicardipineThe serum concentration of Thioridazine can be increased when it is combined with Nicardipine.
NilotinibThe serum concentration of Thioridazine can be increased when it is combined with Nilotinib.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Thioridazine.
OctreotideOctreotide may increase the QTc-prolonging activities of Thioridazine.
OrphenadrineThioridazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
PanobinostatThe serum concentration of Thioridazine can be increased when it is combined with Panobinostat.
ParaldehydeThioridazine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParoxetineThe serum concentration of Thioridazine can be increased when it is combined with Paroxetine.
Peginterferon alfa-2bThe serum concentration of Thioridazine can be decreased when it is combined with Peginterferon alfa-2b.
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Thioridazine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Thioridazine.
PhendimetrazineThioridazine may decrease the stimulatory activities of Phendimetrazine.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Thioridazine.
PhentermineThioridazine may decrease the stimulatory activities of Phentermine.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Thioridazine.
PorfimerThioridazine may increase the photosensitizing activities of Porfimer.
Potassium ChlorideThioridazine may increase the ulcerogenic activities of Potassium Chloride.
PramlintidePramlintide may increase the anticholinergic activities of Thioridazine.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Thioridazine.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Thioridazine.
PromazineThe serum concentration of Thioridazine can be increased when it is combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Thioridazine.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Thioridazine.
PyrimethamineThe serum concentration of Thioridazine can be increased when it is combined with Pyrimethamine.
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Thioridazine.
QuinidineThe serum concentration of Thioridazine can be increased when it is combined with Quinidine.
QuinineThe serum concentration of Thioridazine can be increased when it is combined with Quinine.
RamosetronThioridazine may increase the activities of Ramosetron.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Thioridazine.
RitonavirThe serum concentration of Thioridazine can be increased when it is combined with Ritonavir.
RivastigmineRivastigmine may increase the central neurotoxic activities of Thioridazine.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Thioridazine.
RolapitantThe serum concentration of Thioridazine can be increased when it is combined with Rolapitant.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Thioridazine.
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Thioridazine.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Thioridazine.
SertralineThe serum concentration of Thioridazine can be increased when it is combined with Sertraline.
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Thioridazine.
StiripentolThe serum concentration of Thioridazine can be increased when it is combined with Stiripentol.
SulpirideThe risk or severity of adverse effects can be increased when Thioridazine is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Thioridazine.
SuvorexantThioridazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
TacrineThe therapeutic efficacy of Thioridazine can be decreased when used in combination with Tacrine.
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Thioridazine resulting in a loss in efficacy.
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Thioridazine.
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Thioridazine.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Thioridazine.
TerbinafineThe serum concentration of Thioridazine can be increased when it is combined with Terbinafine.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Thioridazine.
ThalidomideThioridazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThiopentalThe risk or severity of adverse effects can be increased when Thioridazine is combined with Thiopental.
TiclopidineThe serum concentration of Thioridazine can be increased when it is combined with Ticlopidine.
TiotropiumThioridazine may increase the anticholinergic activities of Tiotropium.
TipranavirThe serum concentration of Thioridazine can be increased when it is combined with Tipranavir.
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Thioridazine.
TopiramateThe risk or severity of adverse effects can be increased when Thioridazine is combined with Topiramate.
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Thioridazine.
TranylcypromineThe serum concentration of Thioridazine can be increased when it is combined with Tranylcypromine.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Thioridazine.
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Thioridazine.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Thioridazine.
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Thioridazine.
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Thioridazine.
VerteporfinThioridazine may increase the photosensitizing activities of Verteporfin.
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Thioridazine.
VortioxetineThe serum concentration of Vortioxetine can be increased when it is combined with Thioridazine.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Thioridazine.
ZolpidemThioridazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Seeman P: Atypical neuroleptics: role of multiple receptors, endogenous dopamine, and receptor linkage. Acta Psychiatr Scand Suppl. 1990;358:14-20. [PubMed:1978482 ]
  2. Assie MB, Sleight AJ, Koek W: Biphasic displacement of [3H]YM-09151-2 binding in the rat brain by thioridazine, risperidone and clozapine, but not by other antipsychotics. Eur J Pharmacol. 1993 Jun 24;237(2-3):183-9. [PubMed:7689973 ]
  3. Dimpfel W, Spuler M, Wessel K: Different neuroleptics show common dose and time dependent effects in quantitative field potential analysis in freely moving rats. Psychopharmacology (Berl). 1992;107(2-3):195-202. [PubMed:1352051 ]
  4. Barth VN, Chernet E, Martin LJ, Need AB, Rash KS, Morin M, Phebus LA: Comparison of rat dopamine D2 receptor occupancy for a series of antipsychotic drugs measured using radiolabeled or nonlabeled raclopride tracer. Life Sci. 2006 May 22;78(26):3007-12. Epub 2006 Jan 24. [PubMed:16434058 ]
  5. Carey GJ, Bergman J: Discriminative-stimulus effects of clozapine in squirrel monkeys: comparison with conventional and novel antipsychotic drugs. Psychopharmacology (Berl). 1997 Aug;132(3):261-9. [PubMed:9292626 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD1
Uniprot ID:
P21728
Molecular Weight:
49292.765 Da
References
  1. Hammock RG, Schroeder SR, Levine WR: The effect of clozapine on self-injurious behavior. J Autism Dev Disord. 1995 Dec;25(6):611-26. [PubMed:8720030 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Sleight AJ, Koek W, Bigg DC: Binding of antipsychotic drugs at alpha 1A- and alpha 1B-adrenoceptors: risperidone is selective for the alpha 1B-adrenoceptors. Eur J Pharmacol. 1993 Jul 20;238(2-3):407-10. [PubMed:7691623 ]
  2. Cahir M, King DJ: Antipsychotics lack alpha 1A/B adrenoceptor subtype selectivity in the rat. Eur Neuropsychopharmacol. 2005 Mar;15(2):231-4. [PubMed:15695070 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Cahir M, King DJ: Antipsychotics lack alpha 1A/B adrenoceptor subtype selectivity in the rat. Eur Neuropsychopharmacol. 2005 Mar;15(2):231-4. [PubMed:15695070 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Andree TH, Mikuni M, Tong CY, Koenig JI, Meltzer HY: Differential effect of subchronic treatment with various neuroleptic agents on serotonin2 receptors in rat cerebral cortex. J Neurochem. 1986 Jan;46(1):191-7. [PubMed:2866233 ]
  2. Canton H, Verriele L, Millan MJ: Competitive antagonism of serotonin (5-HT)2C and 5-HT2A receptor-mediated phosphoinositide (PI) turnover by clozapine in the rat: a comparison to other antipsychotics. Neurosci Lett. 1994 Nov 7;181(1-2):65-8. [PubMed:7898773 ]
  3. Burki HR: Binding of psychoactive drugs to rat brain amine receptors, measured ex vivo, and their effects on the metabolism of biogenic amines. Naunyn Schmiedebergs Arch Pharmacol. 1986 Mar;332(3):258-66. [PubMed:2423886 ]
  4. Costall B, Naylor RJ: Behavioural interactions between 5-hydroxytryptophan, neuroleptic agents and 5-HT receptor antagonists in modifying rodent responding to aversive situations. Br J Pharmacol. 1995 Dec;116(7):2989-99. [PubMed:8680734 ]
  5. Morisset S, Sahm UG, Traiffort E, Tardivel-Lacombe J, Arrang JM, Schwartz JC: Atypical neuroleptics enhance histamine turnover in brain via 5-Hydroxytryptamine2A receptor blockade. J Pharmacol Exp Ther. 1999 Feb;288(2):590-6. [PubMed:9918563 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function:
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the delayed rectifying potassium current in heart (IKr). Isoforms USO have no channel activity by themself, but modulates channel characteristics by forming heterotetramers with other isoforms which are r...
Gene Name:
KCNH2
Uniprot ID:
Q12809
Molecular Weight:
126653.52 Da
References
  1. Milnes JT, Witchel HJ, Leaney JL, Leishman DJ, Hancox JC: hERG K+ channel blockade by the antipsychotic drug thioridazine: An obligatory role for the S6 helix residue F656. Biochem Biophys Res Commun. 2006 Dec 8;351(1):273-80. Epub 2006 Oct 23. [PubMed:17056009 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Otani K, Aoshima T: Pharmacogenetics of classical and new antipsychotic drugs. Ther Drug Monit. 2000 Feb;22(1):118-21. [PubMed:10688273 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:11